Lercanidipine Teva

Lercanidipine, the active ingredient in Lercanidipine Teva, is a calcium channel blocker presented as a tablet for oral use. It lowers blood pressure in adults with hypertension.

GNH USA supplies Lercanidipine Teva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium channel blocker used to manage elevated arterial pressure.

- Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. - Isolated systolic hypertension: helps control high systolic readings in older adults. - Cardiovascular risk management: contributes to overall risk reduction when combined with lifestyle measures.

Lercanidipine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially upon standing. - Tachycardia: increased heart rate. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Angioedema: swelling of face, lips, or throat. - Myocardial infarction: rare occurrence of heart attack. - Hepatic enzyme elevation: abnormal liver function tests. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac conduction disturbances: heart block or arrhythmias.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential complications.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Liver function: assess baseline hepatic enzymes and monitor during treatment. - Concomitant antihypertensives: adjust doses to prevent additive blood pressure lowering. - Elderly patients: start at lower dose and titrate cautiously. - Pregnancy and lactation: use only if clearly needed, as safety data are limited. - Store at room temperature: keep in the original container, protect from moisture and light.

Lercanidipine may interact with other medicines that affect its metabolism or blood pressure effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Other antihypertensives (e.g., ACE inhibitors, diuretics): risk of excessive hypotension. - Grapefruit juice: can raise drug exposure and heighten side‑effect risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - NSAIDs: may increase risk of peripheral edema. - Beta‑blockers: can mask tachycardia that signals low blood pressure. - Lipid‑lowering agents (e.g., statins): may modestly raise statin levels. - Diuretics: monitor electrolytes and renal function.